Clinical Research Directory
Browse clinical research sites, groups, and studies.
Citalopram and the Risk of Serious Adverse Events
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Summary
This population-based cohort study aims to evaluate the safety of initiating a new outpatient prescription of citalopram at 20 mg/day (higher dose) compared to 10 mg/day (lower dose) in adults aged 65 years and older with reduced kidney function. The primary research question is whether initiating a higher dose of citalopram (20 mg/day) versus a lower dose (10 mg/day) in older adults with low kidney function (defined as an estimated glomerular filtration rate \[eGFR\] less than 45 mL/min per 1.73 m2, without dialysis or a history of kidney transplantation) is associated with an increased 30-day risk of a composite outcome comprising all-cause hospitalization, all-cause emergency department visits, or all-cause mortality.
Official title: Citalopram Dose and the Risk of Serious Adverse Events in Older Adults With Low Kidney Function: A Population-Based Cohort Study Research Protocol
Key Details
Gender
All
Age Range
66 Years - Any
Study Type
OBSERVATIONAL
Enrollment
7110
Start Date
2008-01-01
Completion Date
2027-12-31
Last Updated
2026-09-14
Healthy Volunteers
No
Interventions
Citalopram 10 MG
The primary exposure of interest will be oral Citalopram at a dose of 10 or 20 mg/day.
Citalopram 20 MG
The primary exposure of interest will be oral Citalopram at a dose of 10 or 20 mg/day.
Locations (1)
London Health Sciences Centre Research Institute
London, Ontario, Canada